Increased exosomal microRNA-21 and microRNA-146a levels in the cervicovaginal lavage specimens of patients with cervical cancer

International Journal of Molecular Sciences

Volumn 15, Issue 1, 2014, Pages 758-773

  Liu, Jie ^a   Sun, Hong ^a   Wang, Xiaoli ^a   Yu, Qun ^a   Li, Shuhong ^a   Yu, Xiaoyan ^a   Gong, Wenwen ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

Cervical cancer; Exosomes; microRNA 146a; microRNA 21

Indexed keywords

CALCIMYCIN; CD63 ANTIGEN; CD9 ANTIGEN; MICRORNA 146A; MICRORNA 21; ANTISENSE OLIGONUCLEOTIDE; MICRORNA; MIRN146 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN;

ARTICLE; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXOSOME; FEMALE; HEPATITIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MTT ASSAY; NORTHERN BLOTTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; COMPLICATION; DRUG EFFECTS; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

ANTIGENS, CD63; ANTIGENS, CD9; CALCIMYCIN; EXOSOMES; FEMALE; HEK293 CELLS; HELA CELLS; HUMANS; MICRORNAS; NEOPLASM STAGING; OLIGONUCLEOTIDES, ANTISENSE; PAPILLOMAVIRUS INFECTIONS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84892171579     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15010758     Document Type: Article

References (57)

1. Kamangar, F.; Dores, G.M.; Anderson, W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006, 24, 2137-2150.
2. International Collaboration of Epidemiological Studies of Cervical, Cancer; Appleby, P.; Beral, V.; Berrington de Gonzalez, A.; Colin, D.; Franceschi, S.; Goodhill, A.; Green, J.; Peto, J.; Plummer, M.; et al. Cervical cancer and hormonal contraceptives: Collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet 2007, 370, 1609-1621.
3. Zur Hausen, H. Papillomavirus infections-A major cause of human cancers. Biochim. Biophys. Acta 1996, 1288, F55-F78.
4. Saslow, D.; Solomon, D.; Lawson, H.W.; Killackey, M.; Kulasingam, S.L.; Cain, J.; Garcia, F.A.; Moriarty, A.T.; Waxman, A.G.; Wilbur, D.C.; et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am. J. Clin. Pathol. 2012, 137, 516-542.
5. Walboomers, J.M.; Jacobs, M.V.; Manos, M.M.; Bosch, F.X.; Kummer, J.A.; Shah, K.V.; Snijders, P.J.; Peto, J.; Meijer, C.J.; Munoz, N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999, 189, 12-19.
6. De Sanjose, S.; Quint, W.G.; Alemany, L.; Geraets, D.T.; Klaustermeier, J.E.; Lloveras, B.; Tous, S.; Felix, A.; Bravo, L.E.; Shin, H.R.; et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11, 1048-1056.
7. Munoz, N.; Bosch, F.X.; de Sanjose, S.; Herrero, R.; Castellsague, X.; Shah, K.V.; Snijders, P.J.; Meijer, C.J.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 2003, 348, 518-527.
8. Schiffman, M.; Castle, P.E.; Jeronimo, J.; Rodriguez, A.C.; Wacholder, S. Human papillomavirus and cervical cancer. Lancet 2007, 370, 890-907.
9. Long, M.J.; Wu, F.X.; Li, P.; Liu, M.; Li, X.; Tang, H. MicroRNA-10a targets CHL1 and promotes cell growth, migration and invasion in human cervical cancer cells. Cancer Lett. 2012, 324, 186-196.
10. Yao, Q.; Xu, H.; Zhang, Q.Q.; Zhou, H.; Qu, L.H. MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem. Biophys. Res. Commun. 2009, 388, 539-542.
11. Ambros, V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 2003, 113, 673-676.
12. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215-233.
13. Brennecke, J.; Hipfner, D.R.; Stark, A.; Russell, R.B.; Cohen, S.M. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 2003, 113, 25-36.
14. Reinhart, B.J.; Slack, F.J.; Basson, M.; Pasquinelli, A.E.; Bettinger, J.C.; Rougvie, A.E.; Horvitz, H.R.; Ruvkun, G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403, 901-906.
15. Qiang, R.; Wang, F.; Shi, L.Y.; Liu, M.; Chen, S.; Wan, H.Y.; Li, Y.X.; Li, X.; Gao, S.Y.; Sun, B.C.; et al. Plexin-B1 is a target of miR-214 in cervical cancer and promotes the growth and invasion of HeLa cells. Int. J. Biochem. Cell Biol. 2011, 43, 632-641.
16. Au Yeung, C.L.; Tsang, T.Y.; Yau, P.L.; Kwok, T.T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011, 30, 2401-2410.
17. Xu, X.M.; Wang, X.B.; Chen, M.M.; Liu, T.; Li, Y.X.; Jia, W.H.; Liu, M.; Li, X.; Tang, H. MicroRNA-19a and-19b regulate cervical carcinoma cell proliferation and invasion by targeting CUL5. Cancer Lett. 2012, 322, 148-158.
18. Tian, R.Q.; Wang, X.H.; Hou, L.J.; Jia, W.H.; Yang, Q.; Li, Y.X.; Liu, M.; Li, X.; Tang, H. MicroRNA-372 is down-regulated and targets cyclin-dependent kinase 2 (CDK2) and cyclin A1 in human cervical cancer, which may contribute to tumorigenesis. J. Biol. Chem. 2011, 286, 25556-25563.
19. Peng, R.Q.; Wan, H.Y.; Li, H.F.; Liu, M.; Li, X.; Tang, H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase 7. J. Biol. Chem. 2012, 287, 14301-14309.
20. Yu, J.; Wang, Y.; Dong, R.; Huang, X.; Ding, S.; Qiu, H. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. J. Cancer Res. Clin. Oncol. 2012, 138, 671-674.
21. Pang, R.T.; Leung, C.O.; Ye, T.M.; Liu, W.; Chiu, P.C.; Lam, K.K.; Lee, K.F.; Yeung, W.S. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 2010, 31, 1037-1044.
22. Cai, N.; Wang, Y.D.; Zheng, P.S. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA 2013, 19, 85-95.
23. Jay, C.; Nemunaitis, J.; Chen, P.; Fulgham, P.; Tong, A.W. miRNA profiling for diagnosis and prognosis of human cancer. DNA Cell Biol. 2007, 26, 293-300.
24. Yu, S.L.; Chen, H.Y.; Yang, P.C.; Chen, J.J. Unique microRNA signature and clinical outcome of cancers. DNA Cell Biol. 2007, 26, 283-292.
25. Hunter, M.P.; Ismail, N.; Zhang, X.; Aguda, B.D.; Lee, E.J.; Yu, L.; Xiao, T.; Schafer, J.; Lee, M.L.; Schmittgen, T.D.; et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS One 2008, 3, e3694.
26. Gilad, S.; Meiri, E.; Yogev, Y.; Benjamin, S.; Lebanony, D.; Yerushalmi, N.; Benjamin, H.; Kushnir, M.; Cholakh, H.; Melamed, N.; et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3, e3148.
27. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA 2008, 105, 10513-10518.
28. Valadi, H.; Ekstrom, K.; Bossios, A.; Sjostrand, M.; Lee, J.J.; Lotvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 2007, 9, 654-659.
29. Johnstone, R.M.; Adam, M.; Hammond, J.R.; Orr, L.; Turbide, C. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem. 1987, 262, 9412-9420.
30. Escola, J.M.; Kleijmeer, M.J.; Stoorvogel, W.; Griffith, J.M.; Yoshie, O.; Geuze, H.J. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J. Biol. Chem. 1998, 273, 20121-20127.
31. Hess, C.; Sadallah, S.; Hefti, A.; Landmann, R.; Schifferli, J.A. Ectosomes released by human neutrophils are specialized functional units. J. Immunol. 1999, 163, 4564-4573.
32. Pant, S.; Hilton, H.; Burczynski, M.E. The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem. Pharmacol. 2012, 83, 1484-1494.
33. Gallo, A.; Tandon, M.; Alevizos, I.; Illei, G.G. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012, 7, e30679.
34. Rabinowits, G.; Gercel-Taylor, C.; Day, J.M.; Taylor, D.D.; Kloecker, G.H. Exosomal microRNA: A diagnostic marker for lung cancer. Clin. Lung Cancer 2009, 10, 42-46.
35. Taylor, D.D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008, 110, 13-21.
36. Kuwabara, Y.; Ono, K.; Horie, T.; Nishi, H.; Nagao, K.; Kinoshita, M.; Watanabe, S.; Baba, O.; Kojima, Y.; Shizuta, S.; et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ. Cardiovasc. Genet. 2011, 4, 446-454.
37. Silverman, J.M.; Reiner, N.E. Exosomes and other microvesicles in infection biology: Organelles with unanticipated phenotypes. Cell. Microbiol. 2011, 13, 1-9.
38. Denzer, K.; Kleijmeer, M.J.; Heijnen, H.F.; Stoorvogel, W.; Geuze, H.J. Exosome: From internal vesicle of the multivesicular body to intercellular signaling device. J. Cell Sci. 2000, 113 (Pt 19), 3365-3374.
39. Thery, C.; Zitvogel, L.; Amigorena, S. Exosomes: Composition, biogenesis and function. Nat. Rev. Immunol. 2002, 2, 569-579.
40. Deftereos, G.; Corrie, S.R.; Feng, Q.; Morihara, J.; Stern, J.; Hawes, S.E.; Kiviat, N.B. Expression of miR-21 and miR-143 in cervical specimens ranging from histologically normal through to invasive cervical cancer. PLoS One 2011, 6, e28423.
41. Lui, W.O.; Pourmand, N.; Patterson, B.K.; Fire, A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007, 67, 6031-6043.
42. Wang, X.; Tang, S.; Le, S.Y.; Lu, R.; Rader, J.S.; Meyers, C.; Zheng, Z.M. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3, e2557.
43. Greco, D.; Kivi, N.; Qian, K.; Leivonen, S.K.; Auvinen, P.; Auvinen, E. Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 2011, 6, e21646.
44. Taganov, K.D.; Boldin, M.P.; Chang, K.J.; Baltimore, D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl. Acad. Sci. USA 2006, 103, 12481-12486.
45. Savina, A.; Furlan, M.; Vidal, M.; Colombo, M.I. Exosome release is regulated by a calcium-dependent mechanism in K562 cells. J. Biol. Chem. 2003, 278, 20083-20090.
46. Aharon, A.; Tamari, T.; Brenner, B. Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells. Thromb. Haemost. 2008, 100, 878-885.
47. Bullerdiek, J.; Flor, I. Exosome-delivered microRNAs of "chromosome 19 microRNA cluster" as immunomodulators in pregnancy and tumorigenesis. Mol. Cytogenet. 2012, 5, 27.
48. Jemal, A.; Center, M.M.; DeSantis, C.; Ward, E.M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol. Biomark. Prev. 2010, 19, 1893-1907.
49. Johannesson, G.; Geirsson, G.; Day, N. The effect of mass screening in Iceland, 1965-74, on the incidence and mortality of cervical carcinoma. Int. J. Cancer 1978, 21, 418-425.
50. Quinn, M.; Babb, P.; Jones, J.; Allen, E. Effect of screening on incidence of and mortality from cancer of cervix in England: Evaluation based on routinely collected statistics. BMJ 1999, 318, 904-908.
51. Sigurdsson, K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int. J. Cancer 1993, 54, 563-570.
52. Nanda, K.; McCrory, D.C.; Myers, E.R.; Bastian, L.A.; Hasselblad, V.; Hickey, J.D.; Matchar, D.B. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann. Intern. Med. 2000, 132, 810-819.
53. Martin-Hirsch, P.; Lilford, R.; Jarvis, G.; Kitchener, H.C. Efficacy of cervical-smear collection devices: A systematic review and meta-analysis. Lancet 1999, 354, 1763-1770.
54. McCrory, D.C.; Matchar, D.B.; Bastian, L.; Datta, S.; Hasselblad, V.; Hickey, J.; Myers, E.; Nanda, K. Evaluation of cervical cytology. Evid. Rep./Technol. Assess. 1999, 1-6.
55. Manos, M.M.; Kinney, W.K.; Hurley, L.B.; Sherman, M.E.; Shieh-Ngai, J.; Kurman, R.J.; Ransley, J.E.; Fetterman, B.J.; Hartinger, J.S.; McIntosh, K.M.; et al. Identifying women with cervical neoplasia: Using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999, 281, 1605-1610.
56. Coutlee, F.; Hankins, C.; Lapointe, N. Comparison between vaginal tampon and cervicovaginal lavage specimen collection for detection of human papillomavirus DNA by the polymerase chain reaction. The Canadian Women's HIV Study Group. J. Med. Virol. 1997, 51, 42-47.
57. Yuyama, K.; Sun, H.; Mitsutake, S.; Igarashi, Y. Sphingolipid-modulated exosome secretion promotes clearance of amyloid-by microglia. J. Biol. Chem. 2012, 287, 10977-10989.